Business Context and Reporting Period
Company: StemCells, Inc. (Note: Metadata listed "Microbot Medical Inc." but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2009
Business Overview: A biopharmaceutical company focused on developing cell-based technologies, specifically human neural stem cells (HuCNS-SC) for central nervous system disorders and human liver engrafting cells. The company has incurred significant operating losses since inception and relies on external financing.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 |
|---|---|---|
| Total Revenue | $253,168 | $575,221 |
| Gross Profit | $111,715 | $374,242 |
| Net Loss | $(5,144,741) | $(21,792,653) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.21) |
| Cash and Cash Equivalents (Sep 30, 2009) | $28,226,515 | |
| Total Assets (Sep 30, 2009) | $44,924,756 | |
| Total Liabilities (Sep 30, 2009) | $19,704,891 | |
| Stockholders' Equity (Sep 30, 2009) | $25,219,865 |
Debt and Liquidity: The company holds approximately $28.2 million in cash and cash equivalents. Total debt obligations include capital lease obligations ($173,094) and bond payables ($898,750). A significant liability of $9.26 million is recorded for the fair value of warrants issued in November 2008.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the nine months ended September 30, 2009, increased by 866% compared to the same period in 2008. This was primarily driven by the consolidation of revenues from the acquisition of Stem Cell Sciences Plc (SCS) operations in April 2009, which contributed product sales and licensing revenue not present in the prior year.
- Operating Expenses: Total operating expenses increased by 10% year-over-year for the nine-month period. Research and Development (R&D) expenses rose 9% due to the inclusion of SCS operations and increased personnel headcount. Selling, General, and Administrative (SG&A) expenses increased 10%, partly due to $692,000 in acquisition-related costs.
- Other Income/Expense: The company recorded a non-cash gain of $1.83 million in the third quarter due to a decrease in the fair value of the warrant liability. Conversely, the nine-month period included a loss of $822,517 related to the change in fair value of this liability.
- Wind-Down Expenses: Expenses related to the Rhode Island facility wind-down decreased in the third quarter (a benefit of $5,679) compared to an expense of $53,636 in the prior year, due to reserve adjustments. However, new wind-down expenses of $310,269 were incurred for the closure of the Australia site.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur substantial operating losses in the foreseeable future. The company has limited liquidity and must obtain significant additional capital to sustain product development, clinical trials, and operations.
- Clinical Progress:
- NCL (Batten Disease): Completed a six-patient Phase I trial in January 2009 showing cells were well-tolerated. Published preclinical data in September 2009 showing delayed motor function loss in a mouse model.
- PMD (Pelizaeus-Merzbacher Disease): FDA approved the IND in December 2008. Plans to initiate a Phase I trial at UCSF Children's Hospital by the end of 2009.
- AMD (Age-related Macular Degeneration): Announced preclinical data in October 2009 showing protection of cone photoreceptors.
- Recent Financing: In November 2009 (subsequent to the period end), the company raised gross proceeds of $12.5 million through a registered direct offering of common stock and warrants.
- Risks and Contingencies:
- Litigation: Ongoing patent infringement litigation against Neuralstem, Inc. regarding six patents. The PTO has upheld the patents as amended, but the litigation remains pending.
- Capital Needs: If cash reserves are exhausted and financing is unavailable, the company may be unable to meet operating obligations or may be required to initiate bankruptcy proceedings.
- Regulatory: Uncertainty regarding FDA approval for clinical testing and the novel nature of stem cell technologies.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $28.2 million cash balance against projected R&D and clinical trial burn rates, given the expectation of continued losses.
- Warrant Liability Volatility: Monitor the $9.26 million warrant liability, as fluctuations in stock price and volatility will create significant non-cash gains or losses impacting net income.
- SCS Integration: Assess the commercial viability of the acquired SCS operations (cell-based assays and reagents) as a near-term revenue source versus the long-term therapeutic pipeline.
- Neuralstem Litigation: Track the status of the consolidated patent infringement suits, as the outcome could impact IP value and incur significant legal costs.
- Rhode Island Wind-Down: Review the assumptions regarding the $4.68 million reserve for the Rhode Island facility, specifically vacancy rates and sublease income projections.